A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Rotavirus W179-9 vaccine (Primary) ; DTaP vaccine; Poliovirus vaccine live oral
  • Indications Diphtheria; Pertussis; Poliomyelitis; Rotavirus infections; Tetanus
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 18 Sep 2017 Results published in the Vaccine
    • 16 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 21 May 2015 Planned End Date changed from 1 May 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top